search
Back to results

Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol (pc-ASTER)

Primary Purpose

Basilar Artery Occlusion

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Contact aspiration Thrombectomy
Stent retriever thrombectomy
Sponsored by
Hopital Foch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Basilar Artery Occlusion focused on measuring Stroke, Basilar artery occlusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age ≥ 18 years

  • AIS with BAO on non-invasive imaging (CT or MRI)
  • Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal
  • Being covered by a national health insurance
  • Informed consent obtained from the patients/his proxy or following an emergency procedure

Exclusion Criteria:

  • Known or suspected pre-existing (chronic) large vessel stenosis / occlusion in the symptomatic territory (basilar artery)
  • Severe contrast medium allergy or absolute contraindication to use of iodinated products
  • Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery
  • Pregnancy (urine or serum beta HCG test for women of child-bearing potential)
  • Person deprived of liberty
  • Patient benefiting from a legal protection (guardianship or curatorship)

Sites / Locations

  • Chu BordeauxRecruiting
  • CHU Caen
  • CHU Limoges
  • CHU Montpellier
  • Chru NancyRecruiting
  • Chu Nantes
  • APHP - Pitié Salpêtrière
  • Fondation Adolphe de RothschildRecruiting
  • CHU de Reims
  • CHU Rennes
  • Hôpital FOCHRecruiting
  • CHU de Tours

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

contact aspiration first line thrombectomy

Stent retriever first line thrombectomy

Arm Description

Patient randomized in this arm will have the first arm thrombectomy by contact aspiration

Patient randomized in this arm will have the first arm thrombectomy by Stent retriever

Outcomes

Primary Outcome Measures

Rate of first pass effect (FPE) defined by complete reperfusion after first device pass
The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy

Secondary Outcome Measures

Rate of complete reperfusion after first-line thrombectomy strategy and at the end of endovascular procedure
mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular. mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion
Rate of successful reperfusion (mTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure
mTICI score is evaluated between 0 to 3. Rate of patients with mTICI score equals to 2b/2c/3 after first-line thrombectomy strategy and at the end of endovascular procedure will be evaluated.
Rate of near to complete reperfusion (mTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure
Rate of Arterial Occlusive Lesion (AOL) recanalization score III after first-line thrombectomy strategy and at the end of endovascular procedure
AOL recanalization score is evaluated between 0 to 3 : 0 indicates no recanalization of the primary occlusive lesion 3 indicates complete recanalization of the primary occlusive lesion with any distal flow
Groin puncture time to successful reperfusion time (evaluated in minutes)
Modified Rankin Score (mRS) at 3 and 12 months
mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.
Rate of good functional outcome at 90-day and at one year defined by a mRS 0-3 or equal to pre-stroke mRS (Modified Rankin Score)
Quality of life at 90 days and 12 months assessed by EuroQol 5D-5L scale
EuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
All cause of mortality at 90-day and 12 months
24-hours change in NIHSS (National Institutes of Health Stroke Scale) from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission.
NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity
Subgroups analysis : Age (≤70 vs. >70 years)
Subgroups analysis :Baseline NIHSS≥10 vs NIHSS<10 (18)
Subgroups analysis : Volume of infarct area assessed by pc-ASPECTS (≤7 vs. >7)
A pc-ASPECTS score of 10 indicates absence of visible ischemic changes in the posterior circulation, and pc-ASPECTS score of 0 indicates ischemic changes in the midbrain, pons, and bilateral thalami, posterior circulation territories, and cerebellar hemispheres
Subgroups analysis : Time from admission of patient in hospital to randomization (≤ 300 vs. > 300 minutes)
Subgroups analysis: Baseline site of thrombi on vascular imaging (Top of the basilar artery vs other adjudicated by the core lab)
Subgroups analysis: Prior use of IV alteplase (yes vs. no)
Subgroups analysis : Collateral status (good versus poor, as adjudicated by the core lab on initial angiogram) with a 0-3 scale
Collateral circulation is estimated by angiography with a 0-3 scale. The collateral status will be categorized as poor collaterals (scores 0-1) and good collaterals (scores 2-3)
Incidence of any intracerebral hemorrhage (ICH), parenchymal hematoma (PH), symptomatic ICH on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24±12h after thrombectomy (according to ECASS3 classification)
ECASS III (European Cooperative Acute Stroke Study) classification : Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2)
Incidence of procedure-related complications defined as arterial perforation, arterial dissection, embolization in a new territory (ENT) and subarachnoid haemorrhage
Cost-effectiveness analysis at 12 months
Incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY]), of Contact Aspiration (CA) first-line thrombectomy compared to standard first-line SR thrombectomy in treatment of AIS due to BAO, from a collective perspective and with a 12-months' time horizon.

Full Information

First Posted
February 14, 2022
Last Updated
February 27, 2023
Sponsor
Hopital Foch
search

1. Study Identification

Unique Protocol Identification Number
NCT05320263
Brief Title
Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol
Acronym
pc-ASTER
Official Title
Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 19, 2022 (Actual)
Primary Completion Date
July 2026 (Anticipated)
Study Completion Date
July 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hopital Foch

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Acute ischemic stroke (AIS) patients with basilar artery occlusion (BAO) present a devastating, life-threatening prognosis. Urgent recanalization with endovascular mechanical thrombectomy is routinely performed in patients with BAO although the level of evidence is lower than that in anterior circulation occlusions (randomization in this population versus medical treatment alone having been impossible in recent studies). Recently, a large retrospective study supports the interest of thrombectomy in this population . Speed and grade of the recanalisation have a major impact on clinical outcome. Favorable outcome at 90 days is strongly associated with the successful recanalization status at the end of the endovascular procedure (OR=4.57, 95%CI=1.24-16.87, P=0.023). First pass effect has been shown to be a strong marker of efficacy of endovascular procedure with significant correlation with clinical outcome. Thrombectomy with Stent retrievers dramatically changed the prognosis of anterior circulation large vessel occlusion strokes and currently used in BAO patients (posterior circulation). Contact aspiration (CA) is currently used in anterior large vessel occlusions (COMPASS trial, Lancet 2019), with similar rates of recanalization and favorable outcomes (Boulanger M, 2019), as well as in BAO patients . However, the benefit of CA compared to SR for the treatment of BAO remains under debate with the superiority of first line CA compared to SR or no difference. Available data are based on retrospective studies with no data from RCT. In this context, a randomized controlled trial is needed to assess the benefit of CA versus SR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Basilar Artery Occlusion
Keywords
Stroke, Basilar artery occlusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
It is planned to include a total of 480 patients (240 per am) to show with a 80% power an 12% increase in FPE rate at end of MT with contact aspiration technique, assuming 23 % of FPE in control arm, 5% of spontaneous recanalization and considering one interim futility analysis
Masking
None (Open Label)
Allocation
Randomized
Enrollment
480 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
contact aspiration first line thrombectomy
Arm Type
Experimental
Arm Description
Patient randomized in this arm will have the first arm thrombectomy by contact aspiration
Arm Title
Stent retriever first line thrombectomy
Arm Type
Sham Comparator
Arm Description
Patient randomized in this arm will have the first arm thrombectomy by Stent retriever
Intervention Type
Procedure
Intervention Name(s)
Contact aspiration Thrombectomy
Intervention Description
The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique. A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature.
Intervention Type
Procedure
Intervention Name(s)
Stent retriever thrombectomy
Intervention Description
The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
Primary Outcome Measure Information:
Title
Rate of first pass effect (FPE) defined by complete reperfusion after first device pass
Description
The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Rate of complete reperfusion after first-line thrombectomy strategy and at the end of endovascular procedure
Description
mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular. mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion
Time Frame
24 hours
Title
Rate of successful reperfusion (mTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure
Description
mTICI score is evaluated between 0 to 3. Rate of patients with mTICI score equals to 2b/2c/3 after first-line thrombectomy strategy and at the end of endovascular procedure will be evaluated.
Time Frame
24 hours
Title
Rate of near to complete reperfusion (mTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure
Time Frame
24 hours
Title
Rate of Arterial Occlusive Lesion (AOL) recanalization score III after first-line thrombectomy strategy and at the end of endovascular procedure
Description
AOL recanalization score is evaluated between 0 to 3 : 0 indicates no recanalization of the primary occlusive lesion 3 indicates complete recanalization of the primary occlusive lesion with any distal flow
Time Frame
24 hours
Title
Groin puncture time to successful reperfusion time (evaluated in minutes)
Time Frame
360 minutes
Title
Modified Rankin Score (mRS) at 3 and 12 months
Description
mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.
Time Frame
12 months
Title
Rate of good functional outcome at 90-day and at one year defined by a mRS 0-3 or equal to pre-stroke mRS (Modified Rankin Score)
Time Frame
12 months
Title
Quality of life at 90 days and 12 months assessed by EuroQol 5D-5L scale
Description
EuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time Frame
12 months
Title
All cause of mortality at 90-day and 12 months
Time Frame
12 months
Title
24-hours change in NIHSS (National Institutes of Health Stroke Scale) from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission.
Description
NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity
Time Frame
24 hours
Title
Subgroups analysis : Age (≤70 vs. >70 years)
Time Frame
24 hours
Title
Subgroups analysis :Baseline NIHSS≥10 vs NIHSS<10 (18)
Time Frame
24 hours
Title
Subgroups analysis : Volume of infarct area assessed by pc-ASPECTS (≤7 vs. >7)
Description
A pc-ASPECTS score of 10 indicates absence of visible ischemic changes in the posterior circulation, and pc-ASPECTS score of 0 indicates ischemic changes in the midbrain, pons, and bilateral thalami, posterior circulation territories, and cerebellar hemispheres
Time Frame
24 hours
Title
Subgroups analysis : Time from admission of patient in hospital to randomization (≤ 300 vs. > 300 minutes)
Time Frame
360 minutes
Title
Subgroups analysis: Baseline site of thrombi on vascular imaging (Top of the basilar artery vs other adjudicated by the core lab)
Time Frame
24 hours
Title
Subgroups analysis: Prior use of IV alteplase (yes vs. no)
Time Frame
24 hours
Title
Subgroups analysis : Collateral status (good versus poor, as adjudicated by the core lab on initial angiogram) with a 0-3 scale
Description
Collateral circulation is estimated by angiography with a 0-3 scale. The collateral status will be categorized as poor collaterals (scores 0-1) and good collaterals (scores 2-3)
Time Frame
24 hours
Title
Incidence of any intracerebral hemorrhage (ICH), parenchymal hematoma (PH), symptomatic ICH on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24±12h after thrombectomy (according to ECASS3 classification)
Description
ECASS III (European Cooperative Acute Stroke Study) classification : Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2)
Time Frame
24 hours
Title
Incidence of procedure-related complications defined as arterial perforation, arterial dissection, embolization in a new territory (ENT) and subarachnoid haemorrhage
Time Frame
hours
Title
Cost-effectiveness analysis at 12 months
Description
Incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY]), of Contact Aspiration (CA) first-line thrombectomy compared to standard first-line SR thrombectomy in treatment of AIS due to BAO, from a collective perspective and with a 12-months' time horizon.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years AIS with BAO on non-invasive imaging (CT or MRI) Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal Being covered by a national health insurance Informed consent obtained from the patients/his proxy or following an emergency procedure Exclusion Criteria: Known or suspected pre-existing (chronic) large vessel stenosis / occlusion in the symptomatic territory (basilar artery) Severe contrast medium allergy or absolute contraindication to use of iodinated products Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery Pregnancy (urine or serum beta HCG test for women of child-bearing potential) Person deprived of liberty Patient benefiting from a legal protection (guardianship or curatorship)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arturo CONSOLI
Phone
0033146251955
Email
a.consoli@hopital-foch.com
First Name & Middle Initial & Last Name or Official Title & Degree
Bertrand LAPERGUE
Phone
0033146255973
Email
b.lapergue@hopital-foch.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arturo CONSOLI
Organizational Affiliation
Study principal investigator
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benjamin GORY
Organizational Affiliation
Scientific director
Official's Role
Study Chair
Facility Information:
Facility Name
Chu Bordeaux
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaultier MARNAT
Email
Gaultier.marnart@chu-bordeaux.fr
Facility Name
CHU Caen
City
Caen
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charlotte BARBIER
Email
barbier-ch@chu-caen.fr
Facility Name
CHU Limoges
City
Limoges
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charbel MOUNAYER
Email
charbel.mounayer@chu-limoges.fr
Facility Name
CHU Montpellier
City
Montpellier
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent COSTALAT
Email
vincent.costalat@chu-montpellier.fr
Facility Name
Chru Nancy
City
Nancy
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin GORY
Email
b.gory@chu-nancy.fr
Facility Name
Chu Nantes
City
Nantes
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hubert DESAL
Email
hubert.desal@chu-nantes.fr
Facility Name
APHP - Pitié Salpêtrière
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric CLARENCON
Email
frederic.clarencon@aphp.fr
Facility Name
Fondation Adolphe de Rothschild
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michel PIOTIN
Email
mpiotin@for.paris
Facility Name
CHU de Reims
City
Reims
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sébastien SOIZE
Email
ssoize@chu-reims.fr
Facility Name
CHU Rennes
City
Rennes
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Christophe FERRE
Email
jean-christophe.ferre@chu-rennes.fr
Facility Name
Hôpital FOCH
City
Suresnes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arturo CONSOLI
Phone
0033146251955
Email
a.consoli@hopital-foch.com
Facility Name
CHU de Tours
City
Tours
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grégoire BOULOUIS
Email
g.boulouis@chu-tours.fr

12. IPD Sharing Statement

Learn more about this trial

Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol

We'll reach out to this number within 24 hrs